SGCIA
EGRX

Smith Graham & Co Investment Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Smith Graham & Co Investment Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-273,099
Closed -$4.31M – 144
2023
Q3 		$4.31M Buy
273,099
+3,648
+1% +$65.5K 0.54% 93
2023
Q2 		$5.24M Buy
269,451
+32,568
+14% +$773K 0.63% 69
2023
Q1 		$6.72M Buy
236,883
+5,661
+2% +$168K 0.82% 49
2022
Q4 		$6.76M Sell
231,222
-799
-0.3% -$25.4K 0.83% 44
2022
Q3 		$6.13M Sell
232,021
-322
-0.1% -$11.8K 0.82% 46
2022
Q2 		$10.3M Sell
232,343
-2,377
-1% -$109K 1.27% 9
2022
Q1 		$11.6M Sell
234,720
-1,531
-0.6% -$73.5K 1.21% 14
2021
Q4 		$12M Sell
236,251
-19,281
-8% -$999K 1.2% 16
2021
Q3 		$14.3M Sell
255,532
-22,040
-8% -$1.08M 1.43% 8
2021
Q2 		$11.9M Sell
277,572
-35,145
-11% -$1.45M 1.05% 24
2021
Q1 		$13.1M Buy
312,717
+128,293
+70% +$5.96M 1.06% 21
2020
Q4 		$8.59M Sell
184,424
-3,374
-2% -$158K 0.79% 47
2020
Q3 		$7.98M Buy
187,798
+29,127
+18% +$1.27M 0.91% 32
2020
Q2 		$7.61M Buy
158,671
+7,628
+5% +$381K 0.92% 37
2020
Q1 		$6.95M Buy
151,043
+11,029
+8% +$553K 1.08% 23
2019
Q4 		$8.41M Sell
140,014
-14,640
-9% -$873K 0.82% 48
2019
Q3 		$8.75M Buy
154,654
+980
+0.6% +$55.1K 0.93% 28
2019
Q2 		$8.56M Buy
153,674
+64,890
+73% +$3.38M 0.92% 30
2019
Q1 		$4.48M Buy
+88,784
New +$3.95M 0.49% 121

Other funds holding EGRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Smith Graham & Co Investment Advisors's EGRX Position: Q4 2023 in Review

Smith Graham & Co Investment Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2023, closing a stake of 273,099 shares — an estimated $4.31M sold.

Smith Graham & Co Investment Advisors first reported a position in EGRX in Q1 2019 and held it in 19 quarters. The position peaked at $14.3M in Q3 2021. 104 funds tracked by Wall St. Rank hold EGRX as of Q4 2023.

  • Smith Graham & Co Investment Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • Smith Graham & Co Investment Advisors sold 273,099 Eagle Pharmaceuticals, Inc. shares in Q4 2023, an estimated $4.31M.
  • Smith Graham & Co Investment Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2019 and held it in 19 quarters.
  • Smith Graham & Co Investment Advisors's Eagle Pharmaceuticals, Inc. position peaked at $14.3M in Q3 2021.
  • 104 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2023.

Based on Smith Graham & Co Investment Advisors's 13F filing for Q4 2023, filed 29 Jan 2024.